Upon approval from the FDA, Addrenex and its licensing partner Sciele Pharma, will launch the drug in the first half of 2009.
Patrick Fourteau, CEO of Sciele, said: “We congratulate Addrenex on this NDA filing with the FDA. Our partnership with Addrenex provides us with the opportunity to further expand and diversify our product portfolio.”